Exelixis

EXEL · NASDAQ

$64.39+$1.71 (+2.73%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $62.68

Latest news

Press releaseOct 15, 4:05 PM ETBusiness Wire
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Press releaseOct 14, 4:07 AM ETPRNewswire
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
Press releaseOct 12, 8:34 PM ETPRNewswire
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
NewsSep 11, 2:02 PM ETVandana Singh
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In
Press releaseSep 1, 4:05 PM ETBusiness Wire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
Press releaseAug 31, 2:30 PM ETBusiness Wire
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
Press releaseAug 19, 7:53 PM ETPRNewswire
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
Press releaseAug 17, 10:09 AM ETPRNewswire
Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky
Press releaseAug 16, 6:24 PM ETBusiness Wire
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
Press releaseAug 13, 10:13 AM ETGlobe Newswire
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Exelixis (EXEL)
Press releaseAug 12, 10:21 AM ETBusiness Wire
EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)
Press releaseAug 11, 10:07 AM ETPRNewswire
EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis
Press releaseAug 10, 6:19 PM ETPRNewswire
Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)
NewsAug 5, 4:08 PM ET
Exelixis Q2 Adj. EPS $0.91 Beats $0.79 Estimate, Sales $628.700M Miss $635.951M Estimate
Press releaseAug 5, 4:05 PM ETBusiness Wire
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Press releaseJul 22, 4:30 PM ETBusiness Wire
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
NewsJun 22, 1:38 PM ETVandana Singh
Exelixis Provides 'A Highly Defensive Investment Profile:' Analyst
Press releaseJun 22, 8:00 AM ETBusiness Wire
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
Press releaseMay 30, 10:00 AM ETBusiness Wire
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
Press releaseMay 27, 4:05 PM ETBusiness Wire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
Press releaseMay 21, 5:00 PM ETBusiness Wire
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
Press releaseMay 19, 8:00 AM ETBusiness Wire
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
Press releaseMay 7, 4:05 PM ETBusiness Wire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
NewsMay 5, 4:10 PM ET
Exelixis Q1 Adj. EPS $0.87 Beats $0.70 Estimate, Sales $610.812M Beat $605.196M Estimate
Press releaseMay 5, 4:05 PM ETBusiness Wire
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
NewsMay 5, 7:12 AM ET
Earnings Scheduled For May 5, 2026
Press releaseApr 21, 4:05 PM ETBusiness Wire
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
NewsMar 2, 3:01 PM ET
Forecasting The Future: 11 Analyst Projections For Exelixis
Press releaseFeb 24, 4:05 PM ETBusiness Wire
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
Press releaseFeb 24, 10:58 AM ETPRNewswire
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
NewsFeb 12, 7:01 AM ET
A Glimpse Into The Expert Outlook On Exelixis Through 10 Analysts
NewsFeb 10, 4:08 PM ET
Earnings Breakdown: Exelixis Q4
Press releaseFeb 10, 4:05 PM ETBusiness Wire
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
NewsFeb 9, 12:01 PM ET
A Peek at Exelixis's Future Earnings
Press releaseFeb 2, 8:00 AM ETBusiness Wire
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
NewsJan 12, 8:05 AM ETAvi Kapoor
Exelixis, Citigroup And Other Big Stocks Moving Lower In Monday's Pre-Market Session
NewsNov 3, 10:03 AM ET
Preview: Exelixis's Earnings
NewsOct 28, 1:40 PM ETVandana Singh
Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer
NewsJul 29, 8:20 AM ETAvi Kapoor
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Exelixis (EXEL)

EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)

EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis

Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)

Exelixis Q2 Adj. EPS $0.91 Beats $0.79 Estimate, Sales $628.700M Miss $635.951M Estimate

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

Exelixis Provides 'A Highly Defensive Investment Profile:' Analyst

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

Exelixis Q1 Adj. EPS $0.87 Beats $0.70 Estimate, Sales $610.812M Beat $605.196M Estimate

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

Earnings Scheduled For May 5, 2026

Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026

Forecasting The Future: 11 Analyst Projections For Exelixis

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March

Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge

A Glimpse Into The Expert Outlook On Exelixis Through 10 Analysts

Earnings Breakdown: Exelixis Q4

Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

A Peek at Exelixis's Future Earnings

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

Exelixis, Citigroup And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Preview: Exelixis's Earnings

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer

Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session